SAREPTA THERAPEUTICS INC (SRPT) Stock Analyst Ratings
USA - NASDAQ:SRPT - US8036071004 - Common Stock
18.81 USD
+0.99 (+5.56%)
18.76 USD
-0.05 (-0.27%)
ChartMill assigns a Buy % Consensus number of 68% to SRPT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 33.01. This target is 75.47% above the current price.
SRPT was analyzed by 35 analysts. The buy percentage consensus is at 68. So analysts seem to be have mildly positive about SRPT.
In the previous month the buy percentage consensus was at a similar level.
SRPT was analyzed by 35 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-05 | Mizuho | Upgrade | Neutral -> Outperform |
| 2025-11-05 | Guggenheim | Maintains | Buy -> Buy |
| 2025-11-05 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-04 | Baird | Maintains | Neutral -> Neutral |
| 2025-10-30 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-09-22 | BMO Capital | Upgrade | Market Perform -> Outperform |
| 2025-09-15 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-09-09 | Leerink Partners | Maintains | Market Perform -> Market Perform |
| 2025-08-25 | HC Wainwright & Co. | Reiterate | Sell -> Sell |
| 2025-08-21 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-08-20 | B of A Securities | Maintains | Underperform -> Underperform |
| 2025-08-15 | Deutsche Bank | Maintains | Sell -> Sell |
| 2025-08-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-07 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-07-30 | Barclays | Upgrade | Underweight -> Equal-Weight |
| 2025-07-29 | Bernstein | Initiate | Market Perform |
| 2025-07-29 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2025-07-29 | Needham | Reiterate | Underperform -> Underperform |
| 2025-07-29 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2025-07-29 | Barclays | Upgrade | Underweight -> Equal-Weight |
| 2025-07-29 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2025-07-29 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-29 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-07-28 | Needham | Reiterate | Underperform -> Underperform |
| 2025-07-25 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2025-07-24 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-24 | Citigroup | Initiate | Sell |
| 2025-07-24 | Jefferies | Maintains | Buy -> Buy |
| 2025-07-23 | B of A Securities | Downgrade | Neutral -> Underperform |
SAREPTA THERAPEUTICS INC / SRPT FAQ
What is the average price target for SAREPTA THERAPEUTICS INC (SRPT) stock?
35 analysts have analysed SRPT and the average price target is 33.01 USD. This implies a price increase of 75.47% is expected in the next year compared to the current price of 18.81.
What is the consensus rating for SRPT stock?
The consensus rating for SAREPTA THERAPEUTICS INC (SRPT) is 68 / 100 . This indicates that analysts generally have a neutral outlook on the stock.